PDF(Pubmed)
Abstract：
The increasing rate of drug resistance often leads to Helicobacter pylori (H. pylori) eradication failure and needs the rescue therapy. Thus, the exploration of new rescue therapeutic regimens is important. The present study was designed to test the beneficial effects of Saccharomyces boulardii (S.boulardii) prior to H. pylori rescue therapy basing on bismuth quadruple.
One hundred H. pylori-infected patients were randomly divided into two groups: study group and control group. Patients in the study group (n=50) underwent two-stages therapy: patients started with S.boulardii monotherapy for 2 weeks, and then tested for H. pylori infection after resting for 4 weeks without any therapy, patients who were still positive for H. pylori continued with bismuth quadruple eradication therapy. For the control group (n=50), all patients were observed and were not treated with any gastric drugs or antibiotics for 6 weeks, then those who were still positive for H. pylori received the same eradication therapy as the study group. Eradication rate, adverse events and the cost-effectiveness of two regimens were analyzed in this study.
The H.pylori eradication rate of ITT (intent-to-treat) analysis and PP (per-protocol) analysis in the first phase of treatment were significantly higher in the study group than the control groups respectively (28.0% vs 2.0%, p<0.001 and 30.4% vs 2.1% p<0.001). For the total treatment effect, there were no significant differences in the eradication rate of ITT analysis (78.0% vs 80.0%) or PP analysis (90.7% vs 88.9%) between the study group and the control group. The cost-effectiveness ratio of the study group was slightly higher than that of the control group (8.95 vs 8.55). There were two patients in the study group and four patients in the control group with the adverse events, respectively. There was no significant difference on the incidence of adverse events between the two groups (p=0.68).
S.boulardii may serve as a beneficial treatment option before H. pylori rescue therapy since it callowed partial patients to avoid reusing bismuth quadruple.
One hundred H. pylori-infected patients were randomly divided into two groups: study group and control group. Patients in the study group (n=50) underwent two-stages therapy: patients started with S.boulardii monotherapy for 2 weeks, and then tested for H. pylori infection after resting for 4 weeks without any therapy, patients who were still positive for H. pylori continued with bismuth quadruple eradication therapy. For the control group (n=50), all patients were observed and were not treated with any gastric drugs or antibiotics for 6 weeks, then those who were still positive for H. pylori received the same eradication therapy as the study group. Eradication rate, adverse events and the cost-effectiveness of two regimens were analyzed in this study.
The H.pylori eradication rate of ITT (intent-to-treat) analysis and PP (per-protocol) analysis in the first phase of treatment were significantly higher in the study group than the control groups respectively (28.0% vs 2.0%, p<0.001 and 30.4% vs 2.1% p<0.001). For the total treatment effect, there were no significant differences in the eradication rate of ITT analysis (78.0% vs 80.0%) or PP analysis (90.7% vs 88.9%) between the study group and the control group. The cost-effectiveness ratio of the study group was slightly higher than that of the control group (8.95 vs 8.55). There were two patients in the study group and four patients in the control group with the adverse events, respectively. There was no significant difference on the incidence of adverse events between the two groups (p=0.68).
S.boulardii may serve as a beneficial treatment option before H. pylori rescue therapy since it callowed partial patients to avoid reusing bismuth quadruple.
摘要：
耐药率的增加往往导致幽门螺杆菌(H.幽门螺杆菌)根除失败，需要抢救治疗。因此，探索新的抢救治疗方案很重要。本研究旨在测试布拉氏酵母菌的有益作用(S.boulardii）在基于铋四联的幽门螺杆菌抢救治疗之前。
将100例幽门螺杆菌感染患者随机分为两组：研究组和对照组。研究组患者（n=50）接受了两个阶段的治疗：患者开始接受布拉氏链球菌单药治疗2周，然后在没有任何治疗的情况下休息4周后测试幽门螺杆菌感染，幽门螺杆菌仍然阳性的患者继续接受铋剂四联根除治疗.对于对照组（n=50），所有患者均接受观察，6周内未接受任何胃用药物或抗生素治疗，幽门螺杆菌仍呈阳性的患者接受与研究组相同的根除治疗.根除率,本研究分析了两种治疗方案的不良事件和成本-效果.
治疗第一阶段的ITT（意向治疗）分析和PP（符合方案）分析的幽门螺杆菌根除率研究组分别明显高于对照组（28.0％vs2.0％，p<0.001和30.4%vs2.1%p<0.001)。对于总的治疗效果，研究组与对照组的ITT分析根除率（78.0％vs80.0％）或PP分析根除率（90.7％vs88.9％）无显着性差异。研究组的成本-效果比略高于对照组(8.95vs8.55)。研究组有2例患者出现不良事件,对照组有4例患者出现不良事件。分别。两组患者的不良事件发生率差异无统计学意义(p=0.68)。
S.在H.pylori抢救治疗之前,布拉替尼可能是一种有益的治疗选择,因为它使部分患者可以避免重复使用铋四联疗法。
将100例幽门螺杆菌感染患者随机分为两组：研究组和对照组。研究组患者（n=50）接受了两个阶段的治疗：患者开始接受布拉氏链球菌单药治疗2周，然后在没有任何治疗的情况下休息4周后测试幽门螺杆菌感染，幽门螺杆菌仍然阳性的患者继续接受铋剂四联根除治疗.对于对照组（n=50），所有患者均接受观察，6周内未接受任何胃用药物或抗生素治疗，幽门螺杆菌仍呈阳性的患者接受与研究组相同的根除治疗.根除率,本研究分析了两种治疗方案的不良事件和成本-效果.
治疗第一阶段的ITT（意向治疗）分析和PP（符合方案）分析的幽门螺杆菌根除率研究组分别明显高于对照组（28.0％vs2.0％，p<0.001和30.4%vs2.1%p<0.001)。对于总的治疗效果，研究组与对照组的ITT分析根除率（78.0％vs80.0％）或PP分析根除率（90.7％vs88.9％）无显着性差异。研究组的成本-效果比略高于对照组(8.95vs8.55)。研究组有2例患者出现不良事件,对照组有4例患者出现不良事件。分别。两组患者的不良事件发生率差异无统计学意义(p=0.68)。
S.在H.pylori抢救治疗之前,布拉替尼可能是一种有益的治疗选择,因为它使部分患者可以避免重复使用铋四联疗法。
